Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab with S-1 and Oxaliplatin in Gastric/GEJ Cancer
NCT02539225Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing S-1/Oxaliplatin + Ramucirumab with S-1/Oxaliplatin + Placebo (2 arms). Primary endpoint: Progression Free Survival up to 25 Months. Started Oct 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02539225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539225.